Participated · Series A · Dec 2024

Biomemory develops DNA-based end-to-end storage solutions, including a recently launched DNA storage card and a planned data‑center appliance. The company uses proprietary synthetic-biology processes to produce long, bio-sourced, biocompatible DNA fragments stored as inert polymers for thousands of years without energy input. Biomemory says its technology offers ultra-high density, longevity, and improved sustainability versus traditional archival media. The company plans to complete first-generation appliance development, accelerate partnerships with industry and cloud providers, and recruit molecular biology and engineering talent. Biomemory aims to scale its molecular data storage to exabyte scale for data center use by 2030. Founded in 2021 as a spinoff of Sorbonne University and CNRS, the company is based in Paris and positions its technology as a complementary, low‑impact archival solution. Biomemory develops a petrol-free DNA synthesis and copy process and DNA data storage solutions that produce long, bio-sourced, biocompatible and bio-secure DNA fragments which can be stored as inert polymers for thousands of years without energy input. The company leverages synthetic biology mechanisms refined over billions of years to assemble DNA and aims to reduce the climate impact of data centers. Biomemory states it currently has the potential to reduce storage costs to $1 per megabyte and expects that further optimization and scaling could bring costs to $1 per terabyte, compared with a ten-year cost of $17 per terabyte for magnetic tape. To achieve this, the company plans to focus on miniaturization, automation and parallelization of an end-to-end integrated and continuous microfluidic DNA assembly device. Biomemory was founded in 2021 and is led by President Erfane Arwani. It has raised seed funding to support technology optimization.